ITOS VS SNDL Stock Comparison

Performance

ITOS
10/100

ITOS returned -55.33% in the last 12 months. Based on SPY's performance of 476.36%, its performance is below average giving it a score of 10 of 100.

SNDL
10/100

SNDL returned -41.15% in the last 12 months. Based on SPY's performance of -21.04%, its performance is below average giving it a score of 10 of 100.

Sentiment

ITOS
72/100

ITOS had a bullish sentiment score of 71.97% across Twitter and StockTwits over the last 12 months. It had an average of 2.33 posts, 2.67 comments, and 4.00 likes per day.

SNDL
72/100

SNDL had a bullish sentiment score of 72.01% across Twitter and StockTwits over the last 12 months. It had an average of 246.01 posts, 458.80 comments, and 1,291.59 likes per day.

Technicals

ITOS
14/100

ITOS receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

SNDL
14/100

SNDL receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

ITOS
10/100

ITOS has missed earnings 5 times in the last 20 quarters.

SNDL
10/100

SNDL has missed earnings 7 times in the last 20 quarters.

Profit

ITOS
31/100

Out of the last 19 quarters, ITOS has had 6 profitable quarters and has increased their profits year over year on 4 of them.

SNDL
10/100

Out of the last 20 quarters, SNDL has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

ITOS
40/100

ITOS has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

SNDL
47/100

SNDL has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

All score calculations are broken down here to help you make more informed investing decisions

iTeos Therapeutics, Inc. Common Stock Summary

Nasdaq / ITOS

Healthcare

Biotechnology

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Sundial Growers Inc. Common Shares Summary

Nasdaq / SNDL

Healthcare

Drug Manufacturers - Specialty & Generic

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Cannabis Operations and Retail Operations segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use markets; and private sale of recreational cannabis through corporate owned and franchised retail cannabis stores. The company also produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

Power up your portfolio